NCT04851964tezepelumabCRSwNPcomorbid asthma
…Introduction and Objectives In the phase 3 WAYPOINT study ( NCT04851964), tezepelumab demonstrated efficacy for the treatment of severe…
1articles mentioning funders
1funder mentions
1distinct funders extracted
0%of mentions human-reviewed
Active filtersEntity: NCT04851964 ×
NCT04851964
This funder is selected. Its supporting articles are shown below.